Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave

11 novembre 2026 mis à jour par: University of Aarhus

Effectiveness of Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave Due to Common Mental Disorders: A Randomized Controlled Trial

The investigators aim to evaluate the effectiveness of Focused Acceptance and Commitment Therapy combined with workplace involvement (FACT-WI) in reducing perceived stress, improving psychological well-being, and supporting return to work among employees on sick leave due to common mental disorders.

Aperçu de l'étude

Description détaillée

In the present study, participants will be randomly assigned to one of two groups, receiving either Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) or treatment as usual (TAU). FACT-WI will be delivered flexibly according to individual needs over a three-month period, with the possibility of involving the participant's immediate manager to support return to work.

  1. It is hypothesized that FACT-WI will be more effective than TAU in reducing perceived stress and improving quality of life over time.
  2. It is hypothesized that participants receiving FACT-WI will return to work more quickly than participants receiving TAU, including both part-time and full-time return to work.
  3. The feasibility and acceptability of FACT-WI will be evaluated.
  4. The number and duration of sessions received, as well as the extent and format of workplace involvement, will be explored.
  5. Managers' experiences of workplace involvement, including its perceived relevance, usefulness, barriers, facilitating factors, and suggestions for improvement, will be explored.

Type d'étude

Interventionnel

Inscription (Estimé)

70

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Astrid Olesen Liboriussen, MSc
  • Numéro de téléphone: 004553356030
  • E-mail: astridol@psy.au.dk

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Inclusion criteria are (i) age ≥ 18 years, (ii) currently being on part-time or full-time sick leave at the start of the study, (iii) symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9) questionnaire and/or symptoms of depression assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10) and/or symptoms of stress measured with the Perceived Stress Scale (PSS-10 ≥ 17), (iv) Danish language proficiency, (v) ability and willingness to give informed consent, (vi) access to either a smartphone, tablet, or computer with video camera. (vii) Be currently employed and anticipate to continue employment within the organizational setting. (viii)) have been employed in the current organization for a minimum of six months.

Exclusion Criteria:

Exclusion criteria are: (i) currently receiving other psychotherapy for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization. (vi) being on sick leave for more than 4 months at the time of inclusion. (vii) a somatic or medical condition that is considered to prevent the participant from RTW. (viii) PTSD symptoms that re-quire treatment beyond the scope of the brief intervention. (ix) having an active Section 56 agreement under the Danish Sickness Benefits Act at the time of inclusion. In addition, potential participants must be clinically assessed as suitable for this brief intervention.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: FACT-WI

Brief ACT-based intervention with optional workplace involvement

Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) is a brief, flexible intervention based on Acceptance and Commitment Therapy (ACT). The intervention aims to increase psychological flexibility, reduce psychological distress, and support return to work.

Participants receive up to 300 minutes of online therapist contact over a period of three months. The intervention is tailored to individual needs and focuses on identifying psychological and work-related barriers, promoting values-based action, and developing strategies to support return to work.

Workplace involvement is offered when relevant and may include written communication with the participant's immediate manager, verbal contact, or a joint meeting between the participant, manager, and therapist. The purpose is to address work-related barriers and facilitate a sustainable return to work. Workplace involvement is voluntary and requires the participant's consent.

Autre: Treatment as Usal (TAU)

Treatment as usual (TAU), including any support or services ordinarily available to employees on sick leave.

Participants allocated to the control group will receive treatment as usual (TAU). They will have access to the usual healthcare and support services available to employees on sick leave, including relevant services provided by the municipality, workplace, or healthcare system.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Perceived stress
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Perceived Stress Scale-10 (PSS-10; Cohen & Williamson, 1988). The scale consists of 10 items rated from 0 to 4, resulting in a total score ranging from 0 to 40. Higher scores indicate higher levels of perceived stress (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Quality of life (well-being)
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

the World Health Organization-5 questionnaire (Bech, 1999; Topp et al., 2015; WHO-5). 5 items are rated on a scale from 0 to 5 with total scores ranging from 0 to 25. Higher scores are indicative of higher levels of life quality (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time to Return to Work (RTW)
Délai: From baseline to 3 months (post-treatment) and 6 months (follow-up).

Time to return to work, including both part-time and full-time return to work. Using administrative sickness absence records.

From baseline to 3 months (post-treatment) and 6 months (follow-up).
Sickness Absence Percentage
Délai: At 3 months (post-treatment) and 6 months (follow-up).

Percentage of scheduled working time lost due to sickness absence, based on administrative sickness absence records. Higher percentages indicate greater sickness absence (i.e., a negative outcome).

At 3 months (post-treatment) and 6 months (follow-up).
Depressive symptoms
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Patient Health Questionnaire-9 (Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000; PHQ-9). 9 items are rated on a scale from 0 to 3, with a potential total range from 0 to 27. Larger scores mean more depressive symptoms (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Anxiety symptoms
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

General Anxiety Disorder-7 (Spitzer et al., 2006; GAD-7). 7 items are rated on scale from 0 to 7 with total scores ranging from 0 to 21. Higher scores are indicative of more symptoms of GAD (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Valued Living
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Valuing Questionnaire (Smout et al., 2014; VQ). 10 items are rated on a scale from 0 to 6 with total scores ranging from 0 to 60. Higher scores a indicative of actions/life being guided by personally held values (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Harm/negative effects
Délai: Measured once at post-treatment (3 months), in the intervention group only.

The Negative Effects Questionnaire (Rozental et al., 2019; NEQ). 32 questions are answered yes/no. If yes, items are rated on a scale from 1 to 5 and participants are asked if the negative effect experience can be attrubuted to the treatment or other crcumstances. Total scores range from 32 to 160 with higher scores indicating more negative effects (i.e., a negative outcome).

Measured once at post-treatment (3 months), in the intervention group only.
Experiental Avoidance
Délai: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Brief Experiential Avoidance Questionnaire (BEAQ; Gámez et al., 2014). The questionnaire consists of 15 items rated from 1 to 6, resulting in a total score ranging from 15 to 90. Higher scores indicate greater experiential avoidance (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Client Satisfaction Questionnaire
Délai: Measured once at 3 months (follow-up), in the intervention group only.

Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979). The questionnaire consists of eight items rated from 1 to 4, resulting in a total score ranging from 8 to 32. Higher scores indicate greater satisfaction with the intervention. The questionnaire will be administered to participants in the FACT-WI group only.

Measured once at 3 months (follow-up), in the intervention group only.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

25 janvier 2027

Achèvement primaire (Estimé)

1 août 2028

Achèvement de l'étude (Estimé)

1 août 2028

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner